<DOC>
	<DOCNO>NCT00610571</DOCNO>
	<brief_summary>Objectives : - To determine maximum tolerate dose oral topotecan administer Temodar patient malignant glioma - To characterize toxicity associate combination oral topotecan Temodar . - To observe patient clinical antitumor response treat oral topotecan Temodar .</brief_summary>
	<brief_title>Ph I Oral Topotecan Temozolomide Patients With Malignant Gliomas</brief_title>
	<detailed_description>Subjects patient glioblastoma ( GBM ) , anaplastic astrocytoma ( AA ) grade 3 great WHO astrocytic , oligodendroglial mixed glial tumor , initially diagnose histologic examination biopsy/resection . Modified classical `` 3+3 '' phase I design used determine maximum tolerate dose topotecan combination Temodar .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histology : GBM , AA grade 3 great WHO astrocytic , oligodendroglial mixed glial tumor initially diagnose histologic exam biopsy/resection Age : &gt; equal 18 year Performance Status : Karnofsky Performance Status &gt; equal 60 % study entry . Renal Function : Serum creatinine &lt; 1.5 mg/dl creatinine clearance &gt; 60 ml/dL . Hematologic Status : The follow baseline study require entry : total granulocyte count &gt; equal 1000/microliter ; platelet count &gt; 100,000/microliter Hepatic Function : Serum SGOT &amp; total bilirubin &lt; equal 2.5 time ULN . Note : All lab parameter must obtain within 1 week registration Consent : Signed informed consent , approve IRB , obtain prior initiate treatment Corticosteroids : For patient currently corticosteroid , patient stable dose 1 week prior study entry , clinically possible . Prior Therapy : Interval least 2 week prior surgical resection prior radiotherapy ( XRT ) 1 week completion chemotherapy toxicity &lt; equal grade 1 &amp; enrollment protocol unless unequivocal evidence progressive disease . Patients Reproductive Potential : Patients must agree practice effective birth control measure study 2 month complete therapy Pregnant breast feed woman woman men reproductive potential practicing adequate contraception . This therapy may associate potential toxicity fetus child exceed minimum risk necessary meet health need mother Active infection require intravenous antibiotic Prior failure either topotecan temozolomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Malignant Gliomas</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>AA</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma Multiform</keyword>
	<keyword>Gliosarcoma</keyword>
</DOC>